We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Kontra Investment Xchange’s Substack by ...

Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s shares closed last Friday at $17.11. Prasad covers the ...

Teva Pharmaceutical (TEVA) stock gains in premarket after the company posted better than expected Q3 2024 financials and ...

We expect them to fuel Teva’s business greatly, especially as the company attempts to get Austedo and Uzedy approved in Europe and Asia. These three drugs made up roughly 10% of company's total ...

Teva Pharmaceutical Industries raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

On October 31, 2024, the European Commission issued a fine of €462.6 million to Teva Pharmaceuticals, citing abuse of its ...

Zacks Research analyst R. Department now forecasts that the company will post earnings of $2.30 per share for the year, up ...

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...

Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in the United States, ...

TEVA) is responding to the European Decision following its investigation into the company’s practices regarding COPAXONE ®-- the standard-of-care treatment for multiple sclerosis – and ...